These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 30142896)

  • 1. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
    Hruska KA; Sugatani T; Agapova O; Fang Y
    Bone; 2017 Jul; 100():80-86. PubMed ID: 28119179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
    Pazianas M; Miller PD
    Am J Kidney Dis; 2021 Oct; 78(4):582-589. PubMed ID: 33774081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
    Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
    J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
    Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
    J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
    Agapova OA; Fang Y; Sugatani T; Seifert ME; Hruska KA
    Kidney Int; 2016 Jun; 89(6):1231-43. PubMed ID: 27165838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption.
    Ono N; Nakashima K; Schipani E; Hayata T; Ezura Y; Soma K; Kronenberg HM; Noda M
    J Biol Chem; 2007 Aug; 282(35):25509-16. PubMed ID: 17500070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TGF-β in a mouse model of high turnover renal osteodystrophy.
    Liu S; Song W; Boulanger JH; Tang W; Sabbagh Y; Kelley B; Gotschall R; Ryan S; Phillips L; Malley K; Cao X; Xia TH; Zhen G; Cao X; Ling H; Dechow PC; Bellido TM; Ledbetter SR; Schiavi SC
    J Bone Miner Res; 2014; 29(5):1141-57. PubMed ID: 24166835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.
    Delgado-Calle J; Hancock B; Likine EF; Sato AY; McAndrews K; Sanudo C; Bruzzaniti A; Riancho JA; Tonra JR; Bellido T
    FASEB J; 2018 May; 32(5):2878-2890. PubMed ID: 29401593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy.
    Williams MJ; Halabi CM; Patel HM; Joseph Z; McCommis K; Weinheimer C; Kovacs A; Lima F; Finck B; Malluche H; Hruska KA
    Am J Physiol Renal Physiol; 2024 May; 326(5):F751-F767. PubMed ID: 38385175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of Wnt signals in bone resorption during physiological and pathological states.
    Maeda K; Takahashi N; Kobayashi Y
    J Mol Med (Berl); 2013 Jan; 91(1):15-23. PubMed ID: 23111637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal and hormonal effects of magnesium deficiency.
    Rude RK; Singer FR; Gruber HE
    J Am Coll Nutr; 2009 Apr; 28(2):131-41. PubMed ID: 19828898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin receptor signaling: a potential therapeutic target for osteoporosis.
    Lotinun S; Pearsall RS; Horne WC; Baron R
    Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.